These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26037622)

  • 21. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
    Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
    Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical hemolytic uremic syndrome due to factor H autoantibody.
    Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
    Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemolytic uremic syndrome recurrence after renal transplantation.
    Loirat C; Fremeaux-Bacchi V
    Pediatr Transplant; 2008 Sep; 12(6):619-29. PubMed ID: 18482212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
    Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
    Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.
    Waters AM; Pappworth I; Marchbank K; Bockenhauer D; Tullus K; Pickering MC; Strain L; Sebire N; Shroff R; Marks SD; Goodship TH; Rees L
    Am J Transplant; 2010 Jan; 10(1):168-72. PubMed ID: 19951285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient.
    Chan MR; Thomas CP; Torrealba JR; Djamali A; Fernandez LA; Nishimura CJ; Smith RJ; Samaniego MD
    Am J Kidney Dis; 2009 Feb; 53(2):321-6. PubMed ID: 18805611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.
    Sana G; Dragon-Durey MA; Charbit M; Bouchireb K; Rousset-Rouvière C; Bérard E; Salomon R; Frémeaux-Bacchi V; Niaudet P; Boyer O
    Pediatr Nephrol; 2014 Jan; 29(1):75-83. PubMed ID: 23868108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
    Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
    Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?
    Hirt-Minkowski P; Schaub S; Mayr M; Schifferli JA; Dickenmann M; Frémeaux-Bacchi V; Steiger J
    Nephrol Dial Transplant; 2009 Nov; 24(11):3548-51. PubMed ID: 19633317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Living-donor kidney transplantation for atypical haemolytic uremic syndrome with pre-emptive eculizumab use.
    Parikova A; Fronek JP; Viklicky O
    Transpl Int; 2015 Mar; 28(3):366-9. PubMed ID: 25256057
    [No Abstract]   [Full Text] [Related]  

  • 31. A newly identified mutation in the complement factor I gene not associated with early post-transplant recurrence of atypical hemolytic-uremic syndrome: a case report.
    Ranghino A; Tognarelli G; Basso E; Messina M; Manzione AM; Daidola G; Segoloni GP
    Transplant Proc; 2013 Sep; 45(7):2785-7. PubMed ID: 24034049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.
    Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P
    Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.
    Fujisawa M; Yasumoto A; Kato H; Sugawara Y; Yoshida Y; Yatomi Y; Nangaku M
    Br J Haematol; 2020 Apr; 189(1):182-186. PubMed ID: 31879952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome.
    Guo WY; Song D; Liu XR; Chen Z; Xiao HJ; Ding J; Sun SZ; Liu HY; Wang SX; Yu F; Zhao MH;
    Pediatr Nephrol; 2019 Feb; 34(2):269-281. PubMed ID: 30315407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series.
    Forbes TA; Bradbury MG; Goodship TH; McKiernan PJ; Milford DV
    Pediatr Transplant; 2013 May; 17(3):E93-9. PubMed ID: 23461281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.
    Donne RL; Abbs I; Barany P; Elinder CG; Little M; Conlon P; Goodship TH
    Am J Kidney Dis; 2002 Dec; 40(6):E22. PubMed ID: 12460067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transplantation in atypical hemolytic uremic syndrome.
    Kavanagh D; Richards A; Goodship T; Jalanko H
    Semin Thromb Hemost; 2010 Sep; 36(6):653-9. PubMed ID: 20865642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome.
    Le Quintrec M; Zuber J; Noel LH; Thervet E; Frémeaux-Bacchi V; Niaudet P; Fridman WH; Legendre C; Dragon-Durey MA
    Am J Transplant; 2009 May; 9(5):1223-9. PubMed ID: 19422347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.
    Ferraris JR; Ramirez JA; Ruiz S; Caletti MG; Vallejo G; Piantanida JJ; Araujo JL; Sojo ET
    Pediatr Nephrol; 2002 Oct; 17(10):809-14. PubMed ID: 12376808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.